Literature DB >> 24798278

Penetration of daptomycin into bone and synovial fluid in joint replacement.

D Montange1, F Berthier2, G Leclerc3, A Serre4, L Jeunet4, M Berard5, P Muret6, L Vettoretti7, J Leroy8, B Hoen9, C Chirouze10.   

Abstract

Daptomycin exhibits clinical activity in the treatment of infections with Gram-positive organisms, including infections due to methicillin-resistant Staphylococcus aureus. However, little is known about its penetration into bone and synovial fluid. The aim of our study was to assess the penetration of daptomycin into bone and synovial fluid after a single intravenous administration. This study was conducted in 16 patients who underwent knee or hip replacement and received a single intravenous dose of 8 mg of daptomycin per kg of body weight prior to surgery. Plasma daptomycin concentrations were measured 1 h after the end of daptomycin infusion and when bone fragments were removed. Daptomycin concentrations were also measured on bone fragments and synovial fluid collected at the same time during surgery. All samples were analyzed with a diode array-high-performance liquid chromatography (HPLC) method. After a single-dose intravenous infusion, bone daptomycin concentrations were above the MIC of daptomycin for Staphylococcus aureus in all subjects, and the median bone penetration percentage was 9.0% (interquartile range [IQR], 4.4 to 11.4). These results support the use of daptomycin in the treatment of Staphylococcus aureus bone and joint infections.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24798278      PMCID: PMC4068525          DOI: 10.1128/AAC.02344-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.

Authors:  Kerry L LaPlante; Suzanne Woodmansee
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

2.  Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.

Authors:  Friederike Traunmüller; Michael V Schintler; Julia Metzler; Stephan Spendel; Oliver Mauric; Martin Popovic; Karl Heinz Konz; Erwin Scharnagl; Christian Joukhadar
Journal:  J Antimicrob Chemother       Date:  2010-04-07       Impact factor: 5.790

Review 3.  Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.

Authors:  Zeina A Kanafani; G Ralph Corey
Journal:  Expert Rev Anti Infect Ther       Date:  2007-04       Impact factor: 5.091

4.  Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis.

Authors:  M Lefebvre; C Jacqueline; G Amador; V Le Mabecque; A Miegeville; G Potel; J Caillon; N Asseray
Journal:  Int J Antimicrob Agents       Date:  2010-09-18       Impact factor: 5.283

5.  Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.

Authors:  Issam Raad; Hend Hanna; Ying Jiang; Tanya Dvorak; Ruth Reitzel; Gassan Chaiban; Robert Sherertz; Ray Hachem
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

Review 6.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.

Authors:  Philip S Stewart; William M Davison; Judith N Steenbergen
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

8.  Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin.

Authors:  Karen Smith; Ana Perez; Gordon Ramage; Curtis G Gemmell; Sue Lang
Journal:  Int J Antimicrob Agents       Date:  2008-12-19       Impact factor: 5.283

9.  Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.

Authors:  D A Figueroa; E Mangini; M Amodio-Groton; B Vardianos; A Melchert; C Fana; W Wehbeh; C M Urban; S Segal-Maurer
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

10.  Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Authors:  Steven N Leonard; Céline Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

View more
  19 in total

1.  Successful Daptomycin Use in a Pediatric Patient With Acute, Bilateral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus aureus.

Authors:  Kelsey L Billups; Jeremy S Stultz
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Sep-Oct

2.  Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats.

Authors:  Melissa J Karau; Suzannah M Schmidt-Malan; Qun Yan; Kerryl E Greenwood-Quaintance; Jayawant Mandrekar; Dario Lehoux; Raymond Schuch; Cara Cassino; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Antimicrobial activity against intraosteoblastic Staphylococcus aureus.

Authors:  Florent Valour; Sophie Trouillet-Assant; Natacha Riffard; Jason Tasse; Sacha Flammier; Jean-Philippe Rasigade; Christian Chidiac; François Vandenesch; Tristan Ferry; Frédéric Laurent
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

4.  Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues.

Authors:  Romain Garreau; Damien Montange; Antoine Grillon; François Jehl; Tristan Ferry; Laurent Bourguignon; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2022-08-16       Impact factor: 5.577

5.  Study on daptomycin use and implementation of an antimicrobial stewardship program.

Authors:  Camille Castel; Arnaud de La Blanchardière; Jocelyn Michon; Vincent Cattoir; Guillaume Saint-Lorant
Journal:  Int J Clin Pharm       Date:  2016-03-07

6.  Low prevalence of tissue detection of cefepime and daptomycin used as empirical treatment during revision for periprosthetic joint infections: results of a prospective multicenter study.

Authors:  O Robineau; E Talagrand-Reboulh; B Brunschweiler; F Jehl; E Beltrand; F Rousseau; N Blondiaux; A Grillon; C Joseph; P Lambotte; P Boyer; Eric Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-20       Impact factor: 3.267

Review 7.  High-Dose Daptomycin and Clinical Applications.

Authors:  Timothy W Jones; Ah Hyun Jun; Jessica L Michal; William J Olney
Journal:  Ann Pharmacother       Date:  2021-02-04       Impact factor: 3.154

Review 8.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

9.  Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin.

Authors:  Jhih-Hang Jiang; Anton Y Peleg
Journal:  Genes (Basel)       Date:  2015-11-30       Impact factor: 4.096

10.  Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center.

Authors:  Sandrine Roux; Florent Valour; Judith Karsenty; Marie-Claude Gagnieu; Thomas Perpoint; Sébastien Lustig; Florence Ader; Benoit Martha; Frédéric Laurent; Christian Chidiac; Tristan Ferry
Journal:  BMC Infect Dis       Date:  2016-02-17       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.